These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 9157985)
1. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Ahmad I; Filep JJ; Franklin JC; Janoff AS; Masters GR; Pattassery J; Peters A; Schupsky JJ; Zha Y; Mayhew E Cancer Res; 1997 May; 57(10):1915-21. PubMed ID: 9157985 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine). Marino-Albernas JR; Bittman R; Peters A; Mayhew E J Med Chem; 1996 Aug; 39(17):3241-7. PubMed ID: 8765506 [TBL] [Abstract][Full Text] [Related]
3. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Chabot MC; Wykle RL; Modest EJ; Daniel LW Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333 [TBL] [Abstract][Full Text] [Related]
4. Growth inhibitory effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Peters AC; Ahmad I; Janoff AS; Pushkareva MY; Mayhew E Lipids; 1997 Oct; 32(10):1045-54. PubMed ID: 9358430 [TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. Powis G; Seewald MJ; Gratas C; Melder D; Riebow J; Modest EJ Cancer Res; 1992 May; 52(10):2835-40. PubMed ID: 1316230 [TBL] [Abstract][Full Text] [Related]
6. Stability of association of 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with liposomes is composition dependent. Mayhew E; Ahmad I; Bhatia S; Dause R; Filep J; Janoff AS; Kaisheva E; Perkins WR; Zha Y; Franklin JC Biochim Biophys Acta; 1997 Oct; 1329(1):139-48. PubMed ID: 9370251 [TBL] [Abstract][Full Text] [Related]
7. Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Pushkareva MY; Wannberg SL; Janoff AS; Mayhew E Cancer Immunol Immunother; 2000 Jan; 48(10):569-78. PubMed ID: 10630309 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Berggren MI; Gallegos A; Dressler LA; Modest EJ; Powis G Cancer Res; 1993 Sep; 53(18):4297-302. PubMed ID: 8395981 [TBL] [Abstract][Full Text] [Related]
9. Cell kill and cytostasis by ET-18-OCH3 and heat. Fujiwara K; Modest EJ; Wallen CA Anticancer Res; 1995; 15(4):1333-8. PubMed ID: 7654017 [TBL] [Abstract][Full Text] [Related]
10. Toxicity and disposition of TLC ELL-12 (liposomal antitumor ether lipid) in Sprague-Dawley rats. Bhamra R; Bolcsak LE; Roberts P; Stevens R; Cavanaugh C; Swenson CE Anticancer Drugs; 2003 Mar; 14(3):183-91. PubMed ID: 12634612 [TBL] [Abstract][Full Text] [Related]
11. Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III. Park YS; Hakomori S; Kawa S; Ruan F; Igarashi Y Cancer Res; 1994 Apr; 54(8):2213-7. PubMed ID: 8174128 [TBL] [Abstract][Full Text] [Related]
12. Dissociation of the effects of the antitumour ether lipid ET-18-OCH3 on cytosolic calcium and on apoptosis. Alonso MT; Gajate C; Mollinedo F; Modolell M; Alvarez J; GarcĂa-Sancho J Br J Pharmacol; 1997 Aug; 121(7):1364-8. PubMed ID: 9257915 [TBL] [Abstract][Full Text] [Related]
13. Decreased sensitivity to 1-O-octadecyl-2-O-methyl-glycerophosphocholine in MCF-7 cells adapted for serum-free growth correlates with constitutive association of Raf-1 with cellular membranes. Samadder P; Arthur G Cancer Res; 1999 Oct; 59(19):4808-15. PubMed ID: 10519389 [TBL] [Abstract][Full Text] [Related]
14. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Koshkina NV; Kleinerman ES; Waidrep C; Jia SF; Worth LL; Gilbert BE; Knight V Clin Cancer Res; 2000 Jul; 6(7):2876-80. PubMed ID: 10914737 [TBL] [Abstract][Full Text] [Related]
15. The antitumor ether lipid 1-Q-octadecyl-2-O-methyl-rac-glycerophosphocholine (ET-18-OCH3) inhibits the association between Ras and Raf-1. Samadder P; Richards C; Bittman R; Bhullar RP; Arthur G Anticancer Res; 2003; 23(3B):2291-5. PubMed ID: 12894505 [TBL] [Abstract][Full Text] [Related]
16. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Perkins WR; Dause RB; Li X; Franklin JC; Cabral-Lilly DJ; Zha Y; Dank EH; Mayhew E; Janoff AS Biochim Biophys Acta; 1997 Jul; 1327(1):61-8. PubMed ID: 9247167 [TBL] [Abstract][Full Text] [Related]
17. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. Lim HJ; Masin D; Madden TD; Bally MB J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545 [TBL] [Abstract][Full Text] [Related]
18. The relationship between cellular ether glycerophospholipid content and sensitivity of cancer cells to 1-O-octadecyl-2-O-methyl-glycerophosphocholine. Zhou X; Lu X; Arthur G Anticancer Res; 1992; 12(5):1659-62. PubMed ID: 1444233 [TBL] [Abstract][Full Text] [Related]
19. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide. Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681 [TBL] [Abstract][Full Text] [Related]
20. Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro. Storme GA; Berdel WE; van Blitterswijk WJ; Bruyneel EA; De Bruyne GK; Mareel MM Cancer Res; 1985 Jan; 45(1):351-7. PubMed ID: 4038380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]